Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN9533 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| REGN9533 | EXPERIMENTAL | Randomized as described in the protocol Escalating Cohorts including Optional Cohorts |
| Placebo | EXPERIMENTAL | Randomized as described in the protocol |
| Name | Type | Description |
|---|---|---|
| REGN9533 | DRUG | Administered per the protocol |
| Matching Placebo | DRUG | Administered per the protocol. |
Key Inclusion Criteria: 1. Has a body mass index between 18 and 32 kg/m2, inclusive 2. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECGs) performed at screening and/or prior to administration of i...
REGN9533 is an investigational small molecule being developed by Regeneron Pharmaceuticals, Inc. It is currently in Phase 1 clinical development. The drug has been studied in a completed trial involving healthy volunteers, with a total enrollment of 72 participants.
REGN9533 is being studied for use in healthy volunteers. The completed Phase 1 trial assessed its safety and tolerability in healthy adults. The drug is not approved for any condition and remains in early clinical development.
REGN9533 is developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company conducted a Phase 1 trial of the drug in healthy volunteers.
REGN9533 is in Phase 1 clinical development. A Phase 1 safety and tolerability study in healthy adults has been completed. The drug is investigational and has not been approved by regulatory authorities.
REGN9533 has one completed clinical trial, identified as NCT06665828. This was a Phase 1 safety and tolerability study in healthy adults, conducted in Belgium with 72 participants. The trial was randomized, double-blind, and controlled.